How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

168,437 results for

Screening Test

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening. (PubMed)

First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening. Down's syndrome occurs when a person has three, rather than two copies of chromosome 21; or the specific area of chromosome 21 implicated in causing Down's syndrome. It is the commonest congenital cause of mental disability and also leads to numerous metabolic and structural problems. It can be life-threatening, or lead to considerable ill health, although some individuals (...) have only mild problems and can lead relatively normal lives. Having a baby with Down's syndrome is likely to have a significant impact on family life.Non-invasive screening based on biochemical analysis of maternal serum or urine, or fetal ultrasound measurements, allows estimates of the risk of a pregnancy being affected and provides information to guide decisions about definitive testing.Before agreeing to screening tests, parents need to be fully informed about the risks, benefits and possible

2017 Cochrane

2. First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening. (PubMed)

First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening. Down's syndrome occurs when a person has three copies of chromosome 21 (or the specific area of chromosome 21 implicated in causing Down's syndrome) rather than two. It is the commonest congenital cause of mental disability. Non-invasive screening based on biochemical analysis of maternal serum or urine, or fetal ultrasound measurements, allows estimates of the risk (...) of a pregnancy being affected and provides information to guide decisions about definitive testing.  Before agreeing to screening tests, parents need to be fully informed about the risks, benefits and possible consequences of such a test. This includes subsequent choices for further tests they may face, and the implications of both false positive (i.e. invasive diagnostic testing, and the possibility that a miscarried fetus may be chromosomally normal) and false negative screening tests (i.e. a fetus

2017 Cochrane

3. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT

HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need (...) . >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} This study found a similar level of protection 10 years after a negative HPV test and 3 years after negative cytology, and suggested triage strategies based on HPV results. {{author}} {{($index , , & . Clare Gilham 1 , Alexandra Sargent 2 , Henry C Kitchener 3 , Julian Peto 1, * 1 Non-Communicable Disease Epidemiology Unit, London School of Hygiene & Tropical Medicine, London, UK 2 Department of Virology

2019 NIHR HTA programme

4. Screening for asymptomatic bacteriuria within the framework of the German maternity guidelines, under special consideration of test methods - Addendum to Commission S13-02

Screening for asymptomatic bacteriuria within the framework of the German maternity guidelines, under special consideration of test methods - Addendum to Commission S13-02 1 Translation of the executive summary of the addendum S16-01 Screening auf asymptomatische Bakteriurie im Rahmen der Mutterschafts-Richtlinien unter besonderer Berücksichtigung der Testmethoden – Addendum zum Auftrag S13-02 (Version 1.0; Status: 19 October 2016). Please note: This document was translated by an external (...) translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. S16-01 Screening for asymptomatic bacteriuria within the framework of the German maternity guidelines, under special consideration of test methods – Addendum to Commission S13-02 1 Extract of addendum S16-01 Version 1.0 Screening for bacteriuria in pregnant women 19 October 2016 Institute for Quality

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

5. Cervical screening: acceptable HPV tests

Cervical screening: acceptable HPV tests Cervical screening: acceptable HPV tests - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Cervical screening: acceptable HPV tests Updated 18 June 2019 Contents © Crown copyright 2019 This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit or write to the Information Policy Team (...) , The National Archives, Kew, London TW9 4DU, or email: . Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. This publication is available at https://www.gov.uk/government/publications/cervical-screening-acceptable-hpv-tests/cervical-screening-acceptable-hpv-tests 1. Introduction The following high risk human papillomavirus ( has published the contract prices for test kits in an NHS Framework. Only test kits detailed

2019 Public Health England

6. Urinary Dipstick Testing for Bladder Cancer Screening: Diagnostic Accuracy, Clinical Effectiveness and Guidelines

Urinary Dipstick Testing for Bladder Cancer Screening: Diagnostic Accuracy, Clinical Effectiveness and Guidelines Urinary Dipstick Testing for Bladder Cancer Screening: Diagnostic Accuracy, Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Urinary Dipstick Testing for Bladder Cancer Screening: Diagnostic Accuracy, Clinical Effectiveness and Guidelines Urinary Dipstick Testing for Bladder Cancer Screening: Diagnostic Accuracy, Clinical Effectiveness and Guidelines (...) Last updated: April 1, 2019 Project Number: RB1320-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the diagnostic accuracy of urinary dipstick testing for bladder cancer screening in asymptomatic adult patients with microscopic hematuria? What is the clinical effectiveness of urinary dipstick testing for bladder cancer screening in asymptomatic adult patients? What are the evidence-based guidelines regarding the use

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

7. HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence – An Update

HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence – An Update HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence – An Update | CADTH.ca Find the information you need HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence – An Update HPV Self-Sampling for Primary Cervical Cancer Screening: A Review (...) of Diagnostic Test Accuracy and Clinical Evidence – An Update Last updated: May 30, 2019 Project Number: RC1124-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the diagnostic test accuracy of self-sampled HPV tests compared with clinician-sampled HPV tests or cytology for asymptomatic cervical cancer screening? What is the clinical evidence regarding the agreement or concordance of self-sampled HPV tests and clinician

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

8. Longer screening intervals are recommended following a negative HPV test in primary cervical screening

Longer screening intervals are recommended following a negative HPV test in primary cervical screening Longer screening intervals are recommended following a negative HPV test in primary cervical screening | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Longer screening intervals are recommended following a negative HPV test in primary cervical screening Article Text Commentary Primary care Longer screening intervals are recommended

2017 Evidence-Based Medicine (Requires free registration)

11. Testing innovative strategies to reduce the social gradient in the uptake of bowel cancer screening: a programme of four qualitatively enhanced randomised controlled trials

Testing innovative strategies to reduce the social gradient in the uptake of bowel cancer screening: a programme of four qualitatively enhanced randomised controlled trials Testing innovative strategies to reduce the social gradient in the uptake of bowel cancer screening: a programme of four qualitatively enhanced randomised controlled trials Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you (...) requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} This research programme found that reducing the social gradient in uptake of bowel cancer screening was difficult but 1 of the 4 interventions tested, 'Enhanced Reminder', had a positive impact. {{author}} {{($index

2017 NIHR HTA programme

12. AIM Clinical Appropriateness Guidelines for Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis

AIM Clinical Appropriateness Guidelines for Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis Appropriate.Safe.Affordable © 2019 AIM Specialty Health 2068-0319b Clinical Appropriateness Guidelines Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis EFFECTIVE MARCH 31, 2019 PROPRIETARY Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2019 Informed Medical Decisions, Inc. All Rights Reserved. 2 Table (...) of Contents Scope 3 Appropriate Use Criteria 3 Carrier Screening for Familial Disease 3 Fragile X 3 Carrier Screening for Common and Ethnic Genetic Diseases 3 Cystic Fibrosis 3 Spinal Muscular Atrophy 4 Hemoglobinopathies 4 Ashkenazi Jewish Carrier Screening 4 Other Ethnicities 5 Carrier Screening Not Clinically Appropriate 5 Preimplantation Genetic Screening and Diagnostic Testing of Embryos 5 Preimplantation Genetic Screening for Common Aneuploidy 6 Prenatal Cell-Free DNA Screening 6 Prenatal Molecular

2019 AIM Specialty Health

13. HPV Testing for Primary Cervical Cancer Screening

HPV Testing for Primary Cervical Cancer Screening HPV Testing for Primary Cervical Cancer Screening | CADTH.ca Find the information you need HPV Testing for Primary Cervical Cancer Screening HPV Testing for Primary Cervical Cancer Screening Published on: March 26, 2019 Project Number: OP0530-000 Product Line: Result type: Report Worldwide, cervical cancer is one of the most frequently diagnosed cancers; however, the incidence of cervical cancer has been decreasing in the past three decades (...) , largely due to routine screening with cytology. HPV is the major risk factor for the development of cervical cancer, with 99% of cervical cancer being associated with HPV. It is one of the most common sexually transmitted infections in the world and about three out of every four sexually active Canadians will have at least one HPV infection at some point in their lives. In view of the anticipated higher sensitivity of HPV testing, some experts and stakeholders have called for HPV testing to be used

2019 CADTH - Optimal Use

14. HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence

HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence | CADTH.ca Find the information you need HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical (...) Evidence Last updated: April 19, 2018 Project Number: RC0981-000 Product Line: Research Type: Other Diagnostics Report Type: Summary with Critical Appraisal Result type: Report Question What is the diagnostic test accuracy of self-sampled HPV tests compared with clinician-sampled HPV tests or cytology for asymptomatic cervical cancer screening? What is the clinical evidence regarding the agreement or concordance of self-sampled HPV tests and clinician-sampled HPV tests or cytology for asymptomatic

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

15. Cytology versus HPV testing for cervical cancer screening in the general population. (PubMed)

Cytology versus HPV testing for cervical cancer screening in the general population. Cervical cancer screening has traditionally been based on cervical cytology. Given the aetiological relationship between human papillomavirus (HPV) infection and cervical carcinogenesis, HPV testing has been proposed as an alternative screening test.To determine the diagnostic accuracy of HPV testing for detecting histologically confirmed cervical intraepithelial neoplasias (CIN) of grade 2 or worse (CIN 2 (...) +), including adenocarcinoma in situ, in women participating in primary cervical cancer screening; and how it compares to the accuracy of cytological testing (liquid-based and conventional) at various thresholds.We performed a systematic literature search of articles in MEDLINE and Embase (1992 to November 2015) containing quantitative data and handsearched the reference lists of retrieved articles.We included comparative test accuracy studies if all women received both HPV testing and cervical cytology

2017 Cochrane

16. Group and Screen Pre-Operative Testing Prior to Laparoscopies: Clinical Benefit and Guidelines

Group and Screen Pre-Operative Testing Prior to Laparoscopies: Clinical Benefit and Guidelines Group and Screen Pre-Operative Testing Prior to Laparoscopies: Clinical Benefit and Guidelines | CADTH.ca Find the information you need Group and Screen Pre-Operative Testing Prior to Laparoscopies: Clinical Benefit and Guidelines Group and Screen Pre-Operative Testing Prior to Laparoscopies: Clinical Benefit and Guidelines Published on: October 20, 2017 Project Number: RB1149-000 Product Line (...) : Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical evidence regarding the use of group and screen pre-operative tests prior to laparoscopies? What are the evidence-based guidelines associated with the use of group and screen pre-operative tests prior to laparoscopies? Key Message Six non-randomized studies were identified regarding the use of group and screen pre-operative tests prior to laparoscopies. Tags diagnostic tests, blood

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

17. Requesting the new Cervical Screening Test: what providers need to know

Requesting the new Cervical Screening Test: what providers need to know Requesting the new Cervical Screening Test: what providers need to know - NPS MedicineWise Log In Menu Featured topics Professional development Publications An independent peer-reviewed journal providing critical commentary on drugs and therapeutics. Timely, independent, evidence-based information on new drugs and medical tests, and changes to the PBS and MBS. Featured topics Talk to a professional Information for consumers (...) and consumers. Featured resources 4 February 2019 4 February 2019 18 October 2018 Featured topic 20 years of helping Australians make better decisions about medicines, medical tests and other health technologies Partner with us Latest projects Search Search Search Search POPULAR Log in Log in All fields are required Email address* Password* Log in Breadcrumb And Text Resize Requesting the new Cervical Screening Test: what providers need to know Requesting the new Cervical Screening Test: what providers need

2018 National Prescribing Service Limited (Australia)

18. Urgent, Non-Screening Fecal Occult Blood Testing for Patients with Suspected Gastrointestinal Bleeding: A Review of Clinical Effectiveness and Guidelines

Urgent, Non-Screening Fecal Occult Blood Testing for Patients with Suspected Gastrointestinal Bleeding: A Review of Clinical Effectiveness and Guidelines Urgent, Non-Screening Fecal Occult Blood Testing for Patients with Suspected Gastrointestinal Bleeding: A Review of Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Urgent, Non-Screening Fecal Occult Blood Testing for Patients with Suspected Gastrointestinal Bleeding: A Review of Clinical Effectiveness (...) and Guidelines Urgent, Non-Screening Fecal Occult Blood Testing for Patients with Suspected Gastrointestinal Bleeding: A Review of Clinical Effectiveness and Guidelines Published on: January 3, 2017 Project Number: RC0839-000 Product Line: Research Type: Other Diagnostics Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of urgent non-screening fecal occult blood testing for patients with suspected gastrointestinal bleeding? What are the evidence

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

19. Hepatitis C Screening in Commercially Insured U.S. Birth-cohort Patients: Factors Associated with Testing and Effect of an EMR-based Screening Alert (PubMed)

Hepatitis C Screening in Commercially Insured U.S. Birth-cohort Patients: Factors Associated with Testing and Effect of an EMR-based Screening Alert Hepatitis C virus (HCV) testing rates among U.S. birth-cohort patients have been studied extensively, limited data exists to differentiate birth-cohort screening from risk- or liver disease-based testing. This study aims to identify factors associated with HCV antibody (HCV-Ab) testing in a group of insured birth cohort patients, to determine true (...) birth cohort testing rates, and to determine whether an electronic medical record (EMR)-driven Best Practice Alert (BPA) would improve birth cohort testing rates.All birth-cohort outpatients between 2010 and 2015 were identified. HCV-Ab test results, clinical, and demographic variables were extracted from the EMR, and factors associated with testing were analyzed by logistic regression. True birth-cohort HCV screening rates were determined by detailed chart review for all outpatient visits during

Full Text available with Trip Pro

2018 Journal of translational internal medicine

20. Newborn Screening ACT Sheet [Low T4 and/or elevated TSH (Primary T4 followup TSH test)] Congenital Hypothyroidism

Newborn Screening ACT Sheet [Low T4 and/or elevated TSH (Primary T4 followup TSH test)] Congenital Hypothyroidism Aimer: This guideline is designed primarily as an educational resource for clinicians to help them provide quality medical care It should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. Adherence to this guideline does not necessarily ensure a successful medical (...) of the date this guideline was adopted, and to consider other medical and scientific information that become available after that date. © American College of Medical Genetics and Genomics, 2012 (Funded in part through MCHB/HRSA/HHS grant #U22MC03957) Newborn Screening ACT Sheet [Low T4 and/or elevated TSH (Primary T4 follow- up TSH test)] Congenital Hypothyroidism Differential Diagnosis: Primary and secondary congenital hypothyroidism (CH), transient CH, thyroxine binding globulin (TBG) deficiency

2018 American College of Medical Genetics and Genomics

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>